January 2006 in “OpenCommons at University of Connecticut (University of Connecticut)” Overexpressing AVP1 and AtNHX1 in plants improves salt tolerance and root hair development.
A molecule called α-ketobutyrate was found to extend lifespan and improve aging-related symptoms in worms and mice by activating certain cellular pathways and may help develop anti-aging treatments for humans.
3 citations
,
December 1975 in “PubMed” ALP and ACP have different roles in dog skin, with ALP aiding growth and maintenance, and ACP involved in breakdown processes.
1 citations
,
August 2025 in “The Egyptian Journal of Internal Medicine” BMI is a simple, cost-effective tool for screening obesity and related diseases.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
April 2023 in “Journal of Investigative Dermatology” Patients were very satisfied with the multidisciplinary group visit for alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
31 citations
,
July 2012 in “Journal of Lipid Research” ACBP is crucial for healthy skin in mice.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
October 1993 in “The Journal of Clinical Pharmacology” October 2020 in “The American journal of gastroenterology” Para-aminobenzoic acid in hair supplements can cause autoimmune hepatitis.
February 2024 in “Research Square (Research Square)” Proteins from Tianshan red deer abomasum have strong anti-inflammatory, anti-tumor, and antioxidant effects.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
2 citations
,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
Baricitinib helps regrow hair in teens with severe alopecia areata.
4 citations
,
June 2024 in “Animals” Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.
1 citations
,
January 2015 in “Research Journal of Pharmacy and Technology” The document's conclusion cannot be provided because the document is not accessible or understandable.
July 2010 in “Hair transplant forum international” A new group called the Asian Association of Hair Restoration Surgeons (AAHRS) has been created.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
The patch effectively promotes hair growth for alopecia areata without pain.
2 citations
,
January 2022 in “Springer eBooks”
16 citations
,
May 2017 in “American Journal of Clinical Dermatology” The document concludes that more research is needed to understand and treat Beard Alopecia Areata due to limited current knowledge and evidence.
11 citations
,
March 2021 in “Dermatology and therapy” Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.